Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04683939 |
|
Recruitment Status :
Terminated
(Sponsor decision)
First Posted : December 24, 2020
Last Update Posted : October 2, 2023
|
Sponsor:
BioNTech SE
Information provided by (Responsible Party):
BioNTech SE
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | July 24, 2023 |
| Actual Study Completion Date : | July 24, 2023 |